|
|
Geographic Atrophy: Rapid Response from ARVO
Geographic atrophy (GA) is a pathological deterioration of the retina seen in the late stages of age-related macular degeneration (AMD). It affects 20% of people with AMD, and its prevalence increases exponentially with age. Until recently, there were no treatment options for GA, but investigation into the complement system and its role in the pathogenesis of GA has led to targeted therapies that have revolutionized the treatment paradigm. Because of the recent approval of one of these therapi... |
|
|
HIV Snippets " A Podcast Series: Optimizing Care in HIV Treatment and Prevention
Antiretroviral therapy (ART) for treating HIV has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already-diverse field of HIV treatment. In this CE activity, participants will listen to expert faculty in a series of 4 podcasts. The faculty will explore various aspects of HIV management, including geographic disparities in pre-exposure prophylaxis (PrEP) implementation, use of 3-dru... |
|
|
Recognition and Referral: Best Practices for Managing Patients with GA
Patients with advanced dry age-related macular degeneration can present with geographic atrophy (GA), a disease that is progressive and increases with age. Although there is no treatment approved by the FDA that halts or reverses GA, a number of drugs in the pipeline are designed to address GA progression, hoping to succeed where previous drug candidates failed. This series of regional, interactive, virtual symposia are designed to educate eye care providers on the importance of diagnosis and ... |
|